Ligand Pharmaceuticals Return on Equity

Ligand Pharmaceuticals (LGNZZ) currently reports a ROE of 2.09%. That is above the Healthcare sector average of -75.84%. Use the charts on this page to explore Ligand Pharmaceuticals's ROE history and peer comparisons.

Ligand Pharmaceuticals's ROE of 2.09% is higher than the Healthcare sector average of -75.84%. That is roughly 102.8% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Ligand Pharmaceuticals's current 2.09% should be judged against Healthcare norms (sector average: -75.84%) and against LGNZZ's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 2.09%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -75.84%. From there, open related valuation or income-statement pages for Ligand Pharmaceuticals, and consider following LGNZZ for alerts when major investors trade the stock.

Ligand Pharmaceuticals is classified in the Healthcare sector. On ROE, it currently shows 2.09% versus a sector average near -75.84%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing LGNZZ with unrelated industries.